Kraig Biocraft Laboratories to launch operations at new Southeast Asia production facility this week

This facility is designed to provide expanded capacity and operational security as Kraig Labs scales up its recombinant spider silk manufacturing. The site will play a key role in supporting the Company’s growth strategy as it prepares for anticipated product deliveries to potential customers and strategic markets.

This inaugural production cycle will include the rearing of the Company’s parent lines for its BAM-1 spider silk hybrid, as well as several new transgenic lines that were introduced into the production environment in the first half of 2025. These next-generation strains are part of the Company’s ongoing development pipeline. These new strains are expected to complement the existing BAM-1 hybrids while delivering higher silk yields, improved silk quality, and enhanced robustness.

“This facility represents a critical step forward in our production capabilities,” said Founder and CEO of Kraig Labs, Kim Thompson. “Our collaboration with government agencies in the region has created a robust platform for sustainable growth, allowing us to expand our operational footprint while maintaining close control over the quality and consistency of our spider silk.”

Kraig Labs expects this production cycle to lay the groundwork for future expansion and delivery readiness of the highest-grade fibers as it continues scaling its proprietary silk technology.